test detects the endogenous substances, which are released during the blood circulation mainly when the heart is damaged or stressed, thereby, assessing risk and directing appropriate therapy that improves clinical outcome in high-risk patients.
The level changes of cardiac marker
Trop I and ECG also confirmed the onset of myocardial infarction at the optimal concentration of salbutamol.
GPBB was the most sensitive and specific cardiac marker
compared to other tested cardiac markers
MB and CKMB in AMI patients during the first 4 h after the onset of chest pain.
The Cardiac Marker
Guidelines Uptake in Europe (CARMAGUE)  study (1) pointed out the current use of evidence-based guidelines for the utilization of cardiac biomarkers in Europe (EU) and North America (NA).
Several years ago, a novel cardiac marker
dubbed NT-proBNP became available for risk appraisal.
Cardioprotective potential of methanol extract of Cyprus rotundus on serum cardiac marker
enzymes (CK-MB, LDH, AST, ALT), serum lipids (cholesterol, triglycerides, LDL, HDL) and antioxidant enzymes in heart tissues (SOD, CAT, peroxidase) was evaluated in isoproterenol (ISO) induced myocardial infarction in rabbits.
Fiomi, which is based in Uppsala, Sweden, is at an advanced stage in developing a panel of point-of-care cardiac marker
assays based on technology that was originally developed by Amic AB.
For this reason, the first-draw specimen for cardiac marker
testing is particularly important (15) because the results of this testing have significant influence on emergent treatment decisions.
According to current guidelines, the results of the cardiac marker
testing should be available to the physician within 30 min ("vein-to-brain" time) to initiate therapy within 60-90 min ("door-to-needle" time) after the patient has arrived at the emergency room or intensive care unit.
AegisPOC allows users to connect with any manufacturer's critical care or POC testing device including blood gases, glucose, coagulation, cardiac marker
devices and more.
Roche Diagnostics (Basel, Switzerland) and Response Biomedical (Vancouver, Canada) announced that Response Biomedical has been granted a nonexclusive license under patent rights of Roche Diagnostics to commercialize NT-proBNP (N-terminal prohormone brain natriuretic peptide), a key cardiac marker
for a broad array of cardiovascular conditions.
This TriMark Publications report describes the specific market segment of the in vitro diagnostics (IVD) market devoted to cardiac marker
testing, including size; growth; industry trends; product development and investment; and clinical measurement devices, reagents and supplies.